HC Wainwright restated their neutral rating on shares of Kezar Life Sciences (NASDAQ:KZR – Free Report) in a report issued on Wednesday morning, Marketbeat Ratings reports.
Kezar Life Sciences Stock Down 3.4 %
NASDAQ:KZR opened at $0.80 on Wednesday. Kezar Life Sciences has a one year low of $0.52 and a one year high of $1.14. The company has a debt-to-equity ratio of 0.05, a current ratio of 9.58 and a quick ratio of 9.58. The company has a market cap of $58.06 million, a PE ratio of -0.57 and a beta of 0.21. The firm’s 50 day simple moving average is $0.61 and its 200 day simple moving average is $0.70.
Kezar Life Sciences (NASDAQ:KZR – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. On average, research analysts anticipate that Kezar Life Sciences will post -1.2 earnings per share for the current year.
Institutional Investors Weigh In On Kezar Life Sciences
About Kezar Life Sciences
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.
Further Reading
- Five stocks we like better than Kezar Life Sciences
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- What is Short Interest? How to Use It
- MarketBeat Week in Review – 9/30 – 10/4
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.